UNITED BIOMEDICAL ORAL AIDS VACCINE PHASE I TRIAL
Executive Summary
UNITED BIOMEDICAL ORAL AIDS VACCINE PHASE I TRIAL will be conducted by the National Institute of Allergy & Infectious Diseases and the Hauppauge, N.Y.-based vaccine manufacturer, the company announced April 18. UBI's vaccine, the first orally administered AIDS vaccine to enter clinical trials, contains a synthetic HIV-1 gp120 V3 loop peptide formulated in a microparticle delivery system. The peptide previously had been evaluated as an injectable vaccine in human volunteers "and found to be safe and capable of generating antibodies that neutralize primary field isolates of HIV-1," UBI noted.